A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

NCT ID: NCT02388529

Last Updated: 2015-10-15

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2015-10-31

Brief Summary

This study is a single-center, randomized, double-blind, placebo-controlled study in patients with stable heart failure to evaluate the safety, tolerability, pharmacokinetics, and efficacy of multiple ascending doses of Bendavia™ (MTP-131) intravenous infusion.

Conditions

Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Low dose

Group Type: EXPERIMENTAL

MTP-131

Intervention Type: DRUG

MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intermediate dose

Group Type: EXPERIMENTAL

MTP-131

Intervention Type: DRUG

MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

High dose

Group Type: EXPERIMENTAL

MTP-131

Intervention Type: DRUG

MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Interventions

MTP-131

MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention Type: DRUG

MTP-131

MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention Type: DRUG

MTP-131

MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention Type: DRUG

Placebo

Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• LVEF ≤45% by 2-D echocardiogram.
• Diagnosis of New York Heart Association Class II or III HF for a minimum of 6 months prior to the Screening Visit.
• HF is considered to be stable, in the judgment of the Principal Investigator and no hospitalization related to HF has occurred within the 1 month prior to the Screening Visit.
• Treatment with appropriate pharmacologic therapy for HF including, but not limited to, angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), and an evidence-based beta blocker for the treatment of HF
• Females of child-bearing potential must have a negative serum pregnancy test at the Screening Visit.
• Written informed consent obtained that strictly adheres to the written guidelines from the local Ethical Committee (EC).

Exclusion Criteria

• Unstable angina pectoris within 1 month before initiation of screening procedures. Unstable angina is defined as the occurrence of chest pain more frequently than usual, pain at rest or upon minimal exertion, or protracted episodes of pain without any discernible trigger, and/or chest pain that persists despite use of vasodilatory therapy (e.g., nitroglycerin).
• Coronary or peripheral artery revascularization procedure within 2 months prior to the Screening Visit.
• An acute myocardial infarction within 3 months prior to the Screening Visit.
• Supine resting heart rate ≥ 100 beats per minute after 5 minutes rest.
• Uncontrolled hypertension defined as a systolic blood pressure (BP) >180 mm Hg or a diastolic BP >110 mm Hg on at least 2 consecutive readings.
• Requirement for valve or other cardiac surgery (e.g., pericardectomy).
• Cardiac surgery or valvuloplasty within 2 month prior to the Screening Visit.
• General surgery within 1 month prior to the Screening Visit.
• Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic left ventricular aneurysm.
• Cerebrovascular accident or transient ischemic attack within 3 months prior to the Screening Visit.
• Liver enzyme (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) elevation >3x the upper limit of normal (ULN).
• Estimated glomerular filtration rate (eGFR) <30 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation.
• Known active drug or alcohol abuse.
• Active infection requiring systemic treatment or surgical intervention.
• Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
• Female patients who are pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stealth BioTherapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jim Carr, PharmD

Role: STUDY_DIRECTOR

Stealth BioTherapeutics Inc.

Sotir Marchev, MD,PhD, FESC

Role: PRINCIPAL_INVESTIGATOR

Bulgaria

Locations

Sevlievo, Gabrovo, Bulgaria

Countries

Bulgaria

Other Identifiers

SPIHF-202

Identifier Type: -

Identifier Source: org_study_id